FREDUN PHARMACEUTICALS LIMITED
Compassionate Healthcare
CIN No : L24239MH1987PLC043662

Date: 29th April, 2026

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Scrip Code: 539730

Sub.: Press Release issued by Fredun Pharmaceuticals Limited

Dear Sir/ Madam,

Please find enclosed press release titled **"Fredun Pharmaceuticals Expands Manufacturing Base with Fifth Facility at Palghar"** issued by Fredun Pharmaceuticals Limited.

Kindly take the same on your records.

Thanking you,

Yours truly,

For **Fredun Pharmaceuticals Limited**

FREDUN NARIMAN MEDHORA

Digitally signed by FREDUN NARIMAN MEDHORA
DN: c=IN, o=Personal, postalCode=400014, st=Maharashtra, serialNumber=F06F6F733147D04D5C3AB31DBBCC8289F5146D25F7EBC171F6E5FF3E749D8E80, cn=FREDUN NARIMAN MEDHORA
Date: 2026.04.29 11:16:43 +05'30'

Fredun Nariman Medhora
Managing Director
DIN: 01745348

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

Fredun Pharmaceuticals Expands Manufacturing Base with Fifth Facility at Palghar

Mumbai – April 29, 2026: – Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India's leading pharmaceutical formulation manufacturing companies with a diversified presence across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products, **has announced the establishment of a new manufacturing facility in Palghar, Maharashtra, marking the addition of its fifth facility.**

Manufacturing Expansion Highlights

- **40,000 sq. ft. New Facility Added**
  Marks a significant step in the Company's expansion journey; expected to be operational by October 2026.
- **50,000 sq. ft. Planned Expansion**
  To be undertaken under strategic growth initiatives.
- **Supports Key Product Categories**
  Veterinary products, supportive nutraceuticals, and pharmaceutical formulations.
- **Expected Operational Benefits**
  Enhanced efficiency, improved production scalability, and ability to meet growing domestic and international demand.
- **Stronger Manufacturing Footprint**
  Integration with existing facilities strengthens presence across pharmaceutical and nutraceutical sectors.

The Company remains committed to maintaining high standards of quality, compliance, and innovation while strengthening its position as a leading manufacturing partner in the healthcare industry.

Commenting on the development, Mr. Fredun Medhora, Managing Director, said: *"As our business continues to expand, we are gradually strengthening our manufacturing footprint to stay aligned with our requirements. With opportunities opening up across our key segments, our focus remains on building a stronger and more scalable foundation."*

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor

Kirin Advisors	**Kirin Advisors Private Limited** Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com